Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.3 CAD | -2.57% | +1.34% | +2.12% |
Mar. 22 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
Mar. 21 | Knight Therapeutics Reports Fourth Quarter Results | MT |
Sales 2024 * | 345M 255M | Sales 2025 * | 359M 265M | Capitalization | 536M 395M |
---|---|---|---|---|---|
Net income 2024 * | 3M 2.21M | Net income 2025 * | 2M 1.48M | EV / Sales 2024 * | 1.55 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.49 x |
P/E ratio 2024 * |
177
x | P/E ratio 2025 * |
145
x | Employees | 725 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.55% |
Latest transcript on Knight Therapeutics Inc.
1 day | -2.57% | ||
1 week | +1.34% | ||
Current month | -2.57% | ||
1 month | -4.50% | ||
3 months | +1.15% | ||
6 months | +18.57% | ||
Current year | +2.12% |
Managers | Title | Age | Since |
---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 55 | 13-10-31 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 16-06-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 14-01-05 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Robert N. Lande
BRD | Director/Board Member | 61 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.19% | 11 M€ | -.--% | ||
0.01% | 735 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 5.3 | -2.57% | 35,930 |
24-03-27 | 5.44 | +0.18% | 28,577 |
24-03-26 | 5.43 | +3.43% | 127,669 |
24-03-25 | 5.25 | -0.38% | 478,154 |
24-03-22 | 5.27 | +0.76% | 78,147 |
Delayed Quote Toronto S.E., March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.12% | 396M | |
+13.52% | 9.63B | |
-7.87% | 5.37B | |
+12.50% | 4.28B | |
+18.09% | 3.71B | |
+42.95% | 2.91B | |
-19.01% | 2.54B | |
-20.66% | 2.37B | |
+17.86% | 1.87B | |
-0.50% | 1.64B |